DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR VENLAFAXINE AND O-DESME THY LVENLA FAXINE: ASSESSING THE IMPACT OF CYP2D6, CYP2C9 AND CYP2C19 GENETIC POLYMORPHISMS

被引：0
|
作者：
Pan, X. [1 ]
Rowland-Yeo, K. [1 ]
机构：
[1] Certara UK, Simcyp Div, Edinburgh, Scotland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-167
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [41] Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro:: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism
    Shon, JH
    Yoon, YR
    Kim, MJ
    Kim, KA
    Lim, YC
    Liu, KH
    Shin, DH
    Lee, CH
    Cha, IJ
    Shin, JG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 552 - 563
  • [42] Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
    Kudzi, William
    Dodoo, Alexander N. O.
    Mills, Jeremy J.
    BMC MEDICAL GENETICS, 2009, 10
  • [43] CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review
    Dorji, Palden Wangyel
    Tshering, Gyem
    Na-Bangchang, Kesara
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (04) : 508 - 524
  • [44] SIMULTANEOUS EVALUATION OF CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP1A2 HYDROXYLATION CAPACITY IN HUMANS
    De Andres, F.
    Paulmichl, M.
    Llerena, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S61 - S61
  • [45] The Effect of Genetic Polymorphisms of Cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on Drug-Resistant Epilepsy in Turkish Children
    Mehmet Seven
    Bahadir Batar
    Selin Unal
    Gozde Yesil
    Adnan Yuksel
    Mehmet Guven
    Molecular Diagnosis & Therapy, 2014, 18 : 229 - 236
  • [46] The Effect of Genetic Polymorphisms of Cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on Drug-Resistant Epilepsy in Turkish Children
    Seven, Mehmet
    Batar, Bahadir
    Unal, Selin
    Yesil, Gozde
    Yuksel, Adnan
    Guven, Mehmet
    MOLECULAR DIAGNOSIS & THERAPY, 2014, 18 (02) : 229 - 236
  • [47] Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide in Chinese subjects
    Zhang, Yifan
    Chen, Xiaoyan
    Lin, Nan
    Zhong, Dafang
    Si, Dayong
    Gu, Yingjie
    Zhou, Hui
    DRUG METABOLISM REVIEWS, 2006, 38 : 161 - 162
  • [48] Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants
    Hiratsuka, Masahiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (11) : 1748 - 1759
  • [49] A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters
    Kanjanasilp, Juntip
    Sawangjit, Ratree
    Phanthaisong, Sirikhwan
    Borihanthanawuth, Wongvaruth
    PHARMACOGENOMICS, 2021, 22 (10) : 629 - 640
  • [50] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
    Brandt, J. T.
    Close, S. L.
    Iturria, S. J.
    Payne, C. D.
    Farid, N. A.
    Ernest, C. S., II
    Lachno, D. R.
    Salazar, D.
    Winters, K. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) : 2429 - 2436
12345